Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients

Table 3 Multivariate Cox regression models for overall survival in the training set^a

Variable	Clinical multivariate analysis		Genomic multivariate analysis		Composite multivariate analysis
Variable	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age		<0.001				<0.001
<65	Reference				Reference
≥65	1.41 (1.19–1.66)	<0.001			1.45 (1.23–1.71)	<0.001
Gender		0.010
Female	Reference
Male	1.25 (1.05–1.49)	0.010
TNM6th stage		<0.001				<0.001
IA	Reference				Reference
IB	1.48 (1.17–1.88)	0.001			1.30 (1.02–1.66)	0.031
II	2.34 (1.82–3.01)	<0.001			2.04 (1.58–2.63)	<0.001
IIIA	4.30 (3.29–5.62)	<0.001			3.70 (2.82–4.86)	<0.001
Combined prognostic classifier				<0.001		<0.001
Absence			Reference		Reference
Uncertainty			1.38 (1.06–1.79)	0.016	1.45 (1.12–1.89)	0.006
Presence			1.98 (1.46–2.70)	<0.001	2.09 (1.54–2.86)	<0.001
Non-overlapping signature				0.001		0.036
Absence			Reference		Reference
Uncertainty			1.22 (0.94–1.58)	0.142	1.07 (0.82–1.39)	0.633
Presence			1.68 (1.24–2.27)	0.001	1.38 (1.01–1.87)	0.040
Neutrophils/plasma cells				0.012		0.004
Low			Reference		Reference
Medium			1.27 (1.03–1.57)	0.027	1.30 (1.06–1.61)	0.014
High			1.34 (1.09–1.65)	0.005	1.39 (1.13–1.71)	0.002

^aHazard ratio (HR) estimated by Cox proportional hazards regression. All statistical tests were two-sided. CI confidence interval

ISSN: 1756-9966